Jay L. Koyner, MD, is an Associate Professor of Medicine in the Section of Nephrology at the University of Chicago. He completed his undergraduate degree in Biophysics at The Johns Hopkins University. He then went on to complete medical school at the State University of New York at Stony Brook where he awarded a degree with distinction in research following completion of a Howard Hughes Medical Institute Research Fellowship. Dr. Koyner completed his internal medicine and nephrology training at the University of Chicago, where he currently serves as the Medical Director of the Inpatient Dialysis Unit and Director of ICU Nephrology. He is an expert in the care of patients at risk for and diagnosed with acute kidney injury (AKI) . He is spoken nationally and internationally on AKI and a variety of topics in the field of Critical Care Nephrology. Over the last decade he has served many roles for the American Society of Nephrology, including being a member of the Acute Kidney Injury Advisory Group, Co-Director of the Critical Care Nephrology pre-course (2014 to 2018), Co-Editor of the Nephrology Self-Assessment Program (NephSAP) for Acute Kidney Injury and Critical Care Nephrology (2016 to 2019) and currently he sits on the Scientific Advisory Board of the National Kidney Foundation. He has served on the editorial review board of the Clinical Journal of the American Society of Nephrology, The American Journal of Nephrology and Advances in Chronic Kidney Disease. In addition to being a dedicated clinician educator, Dr. Koyner’s critical care nephrology research interests have focused on the utilization of plasma and urine biomarkers to improve patient risk stratification and outcomes in the setting of AKI. He has contributed to several multicenter studies investigating biomarkers of AKI, including the TRIBE-AKI study, the Furosemide Stress Test study and several industry sponsored investigations. More recently he has begun developing and implementing an electronic health record derived AKI risk score, with the goal of improving the care of patients at high risk for the development of severe hospital acquired AKI. He has published over 90 peer-reviewed articles and book chapters on AKI and the care of patients with kidney injury in the ICU.
The University of Chicago
Chicago. IL
- Nephrology
2006
The University of Chicago
Chicago
- Internal Medicine
2004
Stony Brook School of Medicine
Stony Brook, NY
MD - Medicine
2001
The Johns Hopkins University
Baltimore, MD
BA - Biophysics
1996
Multicenter Development and Validation of a Multimodal Deep Learning Model to Predict Moderate to Severe Acute Kidney Injury.
Multicenter Development and Validation of a Multimodal Deep Learning Model to Predict Moderate to Severe Acute Kidney Injury. Clin J Am Soc Nephrol. 2025 Apr 15.
PMID: 40232856
Correction: A common longitudinal intensive care unit data format (CLIF) for critical illness research.
Correction: A common longitudinal intensive care unit data format (CLIF) for critical illness research. Intensive Care Med. 2025 Apr; 51(4):836-839.
PMID: 40163136
A common longitudinal intensive care unit data format (CLIF) for critical illness research.
A common longitudinal intensive care unit data format (CLIF) for critical illness research. Intensive Care Med. 2025 Mar; 51(3):556-569.
PMID: 40080116
Acute Kidney Injury and Critical Care Nephrology.
Acute Kidney Injury and Critical Care Nephrology. Adv Kidney Dis Health. 2025 Jan; 32(1):12-23.
PMID: 40175025
Can we use artificial intelligence to better treat acute kidney injury?
Can we use artificial intelligence to better treat acute kidney injury? Intensive Care Med. 2025 Jan; 51(1):160-162.
PMID: 39661141
Biomarker Enrichment in Sepsis-Associated Acute Kidney Injury: Finding High-Risk Patients in the Intensive Care Unit.
Biomarker Enrichment in Sepsis-Associated Acute Kidney Injury: Finding High-Risk Patients in the Intensive Care Unit. Am J Nephrol. 2024; 55(1):72-85.
PMID: 37844555
Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7]).
Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7]). Am J Nephrol. 2023; 54(7-8):281-290.
PMID: 37356428
Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology.
Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology. ASAIO J. 2021 10 01; 67(10):1087-1096.
PMID: 34191753
Not All Sepsis-Associated Acute Kidney Injury Is the Same: There May Be an App for That.
Not All Sepsis-Associated Acute Kidney Injury Is the Same: There May Be an App for That. Clin J Am Soc Nephrol. 2020 11 06; 15(11):1543-1545.
PMID: 33034570
Fluid Overload and Mortality in Patients with Severe Acute Kidney Injury and Extracorporeal Membrane Oxygenation.
Fluid Overload and Mortality in Patients with Severe Acute Kidney Injury and Extracorporeal Membrane Oxygenation. Kidney360. 2020 04 30; 1(4):232-240.
PMID: 35372918
Mid-Career Award
American Society of Nephrology
2019